Phase I Clinical Trial of Locoregional Administration of the Oncolytic Adenovirus ONYX-015 in Combination with Mitomycin-C, Doxorubicin, and Cisplatin Chemotherapy in Patients with Advanced Sarcomas
- 24 February 2009
- book chapter
- Published by Springer Nature
- Vol. 542, 705-717
- https://doi.org/10.1007/978-1-59745-561-9_35
Abstract
Despite many advances in cancer therapy, metastatic disease continues to be incurable in the majority of cancer patients. There ia an need for more efficient and less toxic treatments is this setting. Oncolytic virotherapy represents a novel promising direction in the treatment of cancer. Based on preclinical and clinical data, combination with standard chemotherapy has the potential to further increase the antitumor activity of oncolytic virotherapy in a synergistic manner. We present the design of a phase I clinical trial combining intratumoral injections of the oncolytic adenovirus ONYX-015 with systemic chemotherapy in patients with advanced sarcomas.Keywords
This publication has 26 references indexed in Scilit:
- Phase I–II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomasGene Therapy, 2005
- Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2003
- A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.2003
- Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-Gene-Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian CancerJournal of Clinical Oncology, 2002
- Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activityGene Therapy, 2001
- Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?Gene Therapy, 2001
- Amplification of themdm-2 gene andp53 abnormalities in uterine sarcomasInternational Journal of Cancer, 1997
- An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor CellsScience, 1996
- Blockage by Adenovirus E4orf6 of Transcriptional Activation by the p53 Tumor SuppressorScience, 1996
- Inhibition of p53 transactivation required for transformation by adenovirus early 1B proteinNature, 1992